MCID: CND006
MIFTS: 33

Candida Glabrata

Categories: Rare diseases

Aliases & Classifications for Candida Glabrata

MalaCards integrated aliases for Candida Glabrata:

Name: Candida Glabrata 53

Classifications:



Summaries for Candida Glabrata

MalaCards based summary : Candida Glabrata is related to oral candidiasis and candidiasis. An important gene associated with Candida Glabrata is CSF2 (Colony Stimulating Factor 2), and among its related pathways/superpathways are Th2 Differentiation Pathway and Cytokines and Inflammatory Response. The drugs Caspofungin and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include testes, colon and liver, and related phenotypes are hematopoietic system and immune system

Wikipedia : 75 Candida glabrata is a species of haploid yeast of the genus Candida, previously known as Torulopsis... more...

Related Diseases for Candida Glabrata

Diseases related to Candida Glabrata via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 177)
# Related Disease Score Top Affiliating Genes
1 oral candidiasis 30.7 SKAP2 HTN3
2 candidiasis 30.6 SKAP2 IFNG HTN3 APCS
3 opportunistic mycosis 30.0 SKAP2 IFNG
4 vaginitis 10.6
5 endocarditis 10.6
6 vulvovaginal candidiasis 10.5
7 endophthalmitis 10.5
8 large granular lymphocyte leukemia 10.4 IFNG CSF2
9 denture stomatitis 10.4
10 stomatitis 10.4
11 trichosporonosis 10.4 IFNG CSF2
12 mucormycosis 10.4 IFNG CSF2
13 osteomyelitis 10.4
14 acute cystitis 10.4
15 48,xyyy 10.4
16 human t-cell leukemia virus type 2 10.4 IFNG CSF2
17 carotid artery thrombosis 10.4 IFNG CSF2
18 chorioamnionitis 10.4
19 vulvovaginitis 10.4
20 peritonitis 10.4
21 meconium aspiration syndrome 10.4 IFNG CSF2
22 cyclic neutropenia 10.4 IFNG CSF2
23 amyotrophic lateral sclerosis 3 10.3
24 cytomegalovirus retinitis 10.3 IFNG CSF2
25 cryptococcal meningitis 10.3 IFNG CSF2
26 pyelonephritis 10.3
27 neutropenia 10.3
28 47,xyy 10.3
29 keratitis, hereditary 10.3
30 diarrhea 10.3
31 septic arthritis 10.3
32 cytokine deficiency 10.3
33 overgrowth syndrome 10.3
34 smallpox 10.2 IFNG CSF2
35 pulmonary disease, chronic obstructive 10.2
36 aspergillosis 10.2
37 aspiration pneumonia 10.2
38 infective endocarditis 10.2
39 thrombotic thrombocytopenic purpura 10.2
40 esophagitis 10.2
41 toxic shock syndrome 10.2
42 cystitis 10.2
43 purpura 10.2
44 chorioretinitis 10.2
45 meningitis 10.2
46 prosthetic joint infection 10.2
47 parasitic protozoa infectious disease 10.1 IFNG DHFR
48 hypercholesterolemia, familial, 1 10.1
49 thyroid dyshormonogenesis 3 10.1
50 human immunodeficiency virus type 1 10.1

Graphical network of the top 20 diseases related to Candida Glabrata:



Diseases related to Candida Glabrata

Symptoms & Phenotypes for Candida Glabrata

MGI Mouse Phenotypes related to Candida Glabrata:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.7 APCS CSF2 DHFR IFNG RBPJ RIF1
2 immune system MP:0005387 9.56 APCS CSF2 DHFR IFNG RBPJ RIF1
3 mortality/aging MP:0010768 9.28 APCS CSF2 DHFR IFNG LSS RBPJ

Drugs & Therapeutics for Candida Glabrata

Drugs for Candida Glabrata (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 6)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Caspofungin Approved Phase 4 179463-17-3, 162808-62-0 468682 2826718
2
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
3
Micafungin Approved, Investigational Phase 4 235114-32-6 3081921 477468
4 Antifungal Agents Phase 4
5 Echinocandins Phase 4
6 Anti-Infective Agents Phase 4

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Comparison of Candida Eradication and Serum Cidal Activity of Echinocandins in Patients With Presumptive Candidemia Completed NCT00839540 Phase 4 micafungin;Micafungin;Caspofungin
2 Clinical Conditions and Prevalence of Periodontopathogens in Smokers and Non-smokers After Periodontal Therapy Unknown status NCT02581319
3 Method Comparison Protocol: MALDI Biotyper-Clinical Applications (MBT-CA) Phase 2 Unknown status NCT02098226
4 Retrospective Chart Review of Candida Fungemia Active, not recruiting NCT03827330
5 Open, Prospective, Multicenter Trial to Evaluate the Clinical Significance of Combined Serological (Galactomannan ELISA, 1->3-β-D Glucan Assay) and Molecular (Nested Aspergillus PCR Assay, Multifungal DNA Microarray) Diagnostic Assays to Detect and Characterize Fungal Pathogens in Bronchoalveolar Lavage (BAL) and Blood Samples of Hematological High Risk Patients and to Detect Point Mutations Conferring Azole Resistance Enrolling by invitation NCT01695512
6 Natural History of Atherosclerosis Within the Concept of the Glagovian Artery Remodeling in REAL-world Chest Pain Population Underwent Computed Tomography Angiography and 3D Quantitative Coronary Angiography: Clinical potentIal and safeTY Enrolling by invitation NCT02440646
7 Systemic Fungal Infections in Intensive Care Unit Patients Not yet recruiting NCT03292224

Search NIH Clinical Center for Candida Glabrata

Genetic Tests for Candida Glabrata

Anatomical Context for Candida Glabrata

MalaCards organs/tissues related to Candida Glabrata:

41
Testes, Colon, Liver, Neutrophil, Endothelial, Kidney, Bone

Publications for Candida Glabrata

Articles related to Candida Glabrata:

(show top 50) (show all 3140)
# Title Authors PMID Year
1
Novel 2-indolinones containing a sulfonamide moiety as selective inhibitors of candida β-carbonic anhydrase enzyme. 38
30724625 2019
2
Inhibition of α-, β-, γ-, δ-, ζ- and η-class carbonic anhydrases from bacteria, fungi, algae, diatoms and protozoans with famotidine. 38
30727781 2019
3
Yeast cell wall - Silver nanoparticles interaction: A synergistic approach between surface-enhanced Raman scattering and computational spectroscopy tools. 38
31177002 2019
4
Clove oil nanoemulsion showed potent inhibitory effect against Candida spp. 38
31290755 2019
5
Comparison of fks gene mutations and minimum inhibitory concentrations for the detection of Candida glabrata resistance to micafungin: A systematic review and meta-analysis. 38
31077631 2019
6
Eosinophilic cystitis caused by Candida glabrata: A case report. 38
31380221 2019
7
Mating genotypes and susceptibility profiles of clinical isolates of Candida glabrata from Turkey. 38
31134666 2019
8
Unveiling hákarl: A study of the microbiota of the traditional Icelandic fermented fish. 38
31027819 2019
9
Effects of intrinsic microbial stress factors on viability and physiological condition of yeasts isolated from spontaneously fermented cereal doughs. 38
31174038 2019
10
Precise genome editing using a CRISPR-Cas9 method highlights the role of CoERG11 amino acid substitutions in azole resistance in Candida orthopsilosis. 38
31106355 2019
11
Amphotericin B Induction with Voriconazole Consolidation as Salvage Therapy for FKS-Associated Echinocandin Resistance in Candida glabrata Septic Arthritis and Osteomyelitis. 38
31345844 2019
12
Infectious endocarditis caused by Candida glabrata: evidence of in vivo development of echinocandin resistance. 38
31327188 2019
13
Outcomes of Endourologic Interventions in Patients with Preoperative Funguria. 38
30924689 2019
14
Epidemiology and antifungal susceptibility patterns of Candida isolates from Greek women with vulvovaginal candidiasis. 38
31132175 2019
15
Essential Role for the Phosphatidylinositol 3,5-Bisphosphate Synthesis Complex in Caspofungin Tolerance and Virulence in Candida glabrata. 38
31138567 2019
16
A new inducible CRISPR-Cas9 system useful for genome editing and study of DSB repair in Candida glabrata. 38
31423617 2019
17
Usefulness of a multiplex PCR for the rapid identification of Candida glabrata species complex in Mexican clinical isolates. 38
31411267 2019
18
Impact of the major Candida glabrata triazole resistance determinants on the activity of the novel investigational tetrazoles VT-1598 and VT-1161. 38
31383660 2019
19
Label-free quantitative proteomics in Candida yeast species: technical and biological replicates to assess data reproducibility. 38
31370875 2019
20
Attenuating the emergence of anti-fungal drug resistance by harnessing synthetic lethal interactions in a model organism. 38
31425501 2019
21
Attenuated apoptotic BAX expression as a xenobiotic reporter in Saccharomyces cerevisiae. 38
31291458 2019
22
Biosynthesis and characterization of sophorolipid biosurfactant by Candida spp.: Application as food emulsifier and antibacterial agent. 38
30992159 2019
23
Fluconazole Resistance in Isolates of Uncommon Pathogenic Yeast Species from the United Kingdom. 38
31182537 2019
24
The siderophore transporter Sit1 determines susceptibility to the antifungal VL-2397. 38
31405865 2019
25
In vitro evaluation of the effectiveness of alkaline peroxide solutions in reducing the viability of specific biofilms. 38
31436941 2019
26
Repurposing the thrombopoietin receptor agonist eltrombopag as an anticryptococcal agent. 38
31297540 2019
27
The first reported case of colonic infection caused by Candida glabrata. 38
31317758 2019
28
Moonlighting proteins are variably exposed at the cell surfaces of Candida glabrata, Candida parapsilosis and Candida tropicalis under certain growth conditions. 38
31269895 2019
29
Trk1, the sole potassium-specific transporter in Candida glabrata, contributes to the proper functioning of various cell processes. 38
31346773 2019
30
A Rare Case of Candida Pericarditis Associated with Esophagopericardial Fistula. 38
31281180 2019
31
In Vitro Activity of Fenticonazole against Candida and Bacterial Vaginitis Isolates Determined by Mono- or Dual-Species Testing Assays. 38
31061161 2019
32
Inhibition of Biofilm Formation by Candida albicans and Polymicrobial Microorganisms by Nepodin via Hyphal-Growth Suppression. 38
31055910 2019
33
Rapid antifungal susceptibility testing of Candida glabrata isolates against anidulafungin from positive blood culture by MBT ASTRA. 38
31285227 2019
34
Spontaneous fungal peritonitis: Micro-organisms, management and mortality in liver cirrhosis-A systematic review. 38
31388401 2019
35
The glyoxylate cycle and alternative carbon metabolism as metabolic adaptation strategies of Candida glabrata: perspectives from Candida albicans and Saccharomyces cerevisiae. 38
31301737 2019
36
Low Level of Antifungal Resistance in Iranian Isolates of Candida glabrata Recovered from Blood Samples in a Multicenter Study from 2015 to 2018 and Potential Prognostic Values of Genotyping and Sequencing of PDR1. 38
30936110 2019
37
Population Pharmacokinetics of Anidulafungin in Critically Ill Patients. 38
31061150 2019
38
Candidaemia in an Irish intensive care unit setting between 2004 and 2018 reflects increased incidence of Candida glabrata. 38
30668957 2019
39
Effect of Optisol Supplementation With 0.255 μg/mL Amphotericin B on Elimination of Yeast at 5°C. 38
30998618 2019
40
Breastmilk and NICU surfaces are potential sources of fungi for infant mycobiomes. 38
30905830 2019
41
Antimycotic Efficacy and Safety of a New Cold Corneal Storage Medium by Time-Kill and Toxicity Studies. 38
31335527 2019
42
Surgical Management of a Chronic Neck Abscess in a U.S. Navy Bottlenose Dolphin. 38
30793195 2019
43
In Vitro Antifungal Effect of Acrylic Corneal Glue (N-Butyl-2-Cyanoacrylate). 38
31335535 2019
44
Effect of Bay Leaves Essential Oil Concentration on the Properties of Biodegradable Carboxymethyl Cellulose-Based Edible Films. 38
31344962 2019
45
Isolation of Candida in the blood cultures of patients admitted to the Emergency Room in a tertiary care hospital. 38
31377147 2019
46
Mode of action and anti-Candida activity of Artemisia annua mediated-synthesized silver nanoparticles. 38
31378442 2019
47
Oral Candida colonization in xerostomic postradiotherapy head and neck cancer patients. 38
31257663 2019
48
Resistance of Candida to azoles and echinocandins worldwide. 38
30965100 2019
49
Probiotics as antifungal agents: Experimental confirmation and future prospects. 38
31071354 2019
50
Hormones modulate Candida vaginal isolates biofilm formation and decrease their susceptibility to azoles and hydrogen peroxide. 38
31254346 2019

Variations for Candida Glabrata

Expression for Candida Glabrata

Search GEO for disease gene expression data for Candida Glabrata.

Pathways for Candida Glabrata

Pathways related to Candida Glabrata according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.62 RBPJ IFNG
2 10.09 IFNG CSF2

GO Terms for Candida Glabrata

Cellular components related to Candida Glabrata according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.1 TPSAB1 IFNG HTN3 HTN1 CSF2 APCS

Biological processes related to Candida Glabrata according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 defense response to bacterium GO:0042742 9.61 RBPJ HTN3 HTN1
2 humoral immune response GO:0006959 9.48 RBPJ IFNG
3 antimicrobial humoral response GO:0019730 9.46 HTN3 HTN1
4 cholesterol biosynthetic process GO:0006695 9.4 SQLE LSS
5 killing of cells of other organism GO:0031640 9.37 HTN3 HTN1
6 biomineral tissue development GO:0031214 9.32 HTN3 HTN1
7 regulation of cholesterol biosynthetic process GO:0045540 9.26 SQLE LSS
8 defense response to fungus GO:0050832 9.16 HTN3 HTN1
9 myeloid dendritic cell differentiation GO:0043011 8.96 RBPJ CSF2
10 positive regulation of interleukin-23 production GO:0032747 8.62 IFNG CSF2

Sources for Candida Glabrata

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....